As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

If you’ve been paying attention to the weight loss world, you’ve probably heard about GLP-1 receptor agonists like Ozempic, ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

The company will add additional sales for the diagnostic testing business providing a shift in the business and hopefully a focus away from the GLP-1s. Hims has already predicted the launch of ...

Semaglutide and other newer GLP-1 drugs are known to be far more effective ... researchers published findings from the first controlled clinical trial testing semaglutide for alcohol dependence ...

Unlike many oral small-molecule GLP-1 therapies being developed—whose ... manufacturing studies necessary to support human clinical testing of BLX-7006. With these critical studies underway ...